CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 50 enrolled
Drug / intervention
Cervirondevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04735705
NCT04735705N/ACompleted

A Prospective, Open-Label, Pilot, Multicentric Clinical Investigation to Evaluate the Performance and Safety of Cerviron Ovules® in the Local Treatment of Non-Specific or Endogenous, Symptomatic Vaginitis

Perfect Care Distribution·interventional·Posted Feb 3, 2021·Updated Nov 22, 2023

In Brief

A clinical study evaluating Cerviron for Vaginitis and Vulvovaginitis. Completed, enrolled 50 participants across 2 sites.

Detailed Summary

CYRON is a Prospective, Open-Label, Pilot, Multicentric Clinical Investigation to Evaluate the Performance and Safety of Cerviron Ovules® in the Local Treatment of Non-Specific or Endogenous, Symptomatic Vaginitis. The primary objective is to assess the therapeutic performance and tolerability of Cerviron® Ovules in patients with symptomatic, non-specific, non-infectious vaginitis, and endogenous symptomatic infections. The secondary objective of this clinical investigation is the assessment of performance of the medical device by several additionally clinical outcomes (vaginal discharge, vaginal pH, microscopic characteristics of inflammatory cells and characteristics of vaginal microflora). Participants will also evaluate the degree of satisfaction related to the use of the medical device.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesRomania
CollaboratorsMDX Research

Timeline

N/ACompletedFinished
202120222023202420252026
First PostedFeb 3, 2021
Enrollment StartApr 1, 2021
Primary CompletionSep 9, 2021
TodayJul 2, 2026
Enrollment to primary: 5 monthsPosted 5.4 years ago

Interventions

Cervirondevice

Cerviron ovules ® is a class IIb medical device indicated as adjuvant in the treatment of acute and chronic vulvovaginitis of mechanical etiology, caused by changes of vaginal pH and changes of the vaginal flora. It is also used in cervical lesions of mechanical origin as it favors the healing and re-epithelialization processes and reduces the proliferation of endogenous pathogens.